rat monoclonal anti cd34 antibody  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat monoclonal anti cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    1) Product Images from "DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells"

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    Journal: bioRxiv

    doi: 10.1101/2023.01.08.523169

    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Figure Legend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Techniques Used: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay

    rat monoclonal anti cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat monoclonal anti cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    1) Product Images from "DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells"

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    Journal: bioRxiv

    doi: 10.1101/2023.01.08.523169

    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Figure Legend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Techniques Used: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay

    rat anti mouse cd34 mab  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34 mab
    Rat Anti Mouse Cd34 Mab, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 mab/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 mab - by Bioz Stars, 2024-04
    86/100 stars

    Images

    rat anti mouse cd34 mab  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34 mab
    Rat Anti Mouse Cd34 Mab, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 mab/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 mab - by Bioz Stars, 2024-04
    86/100 stars

    Images

    rat anti mouse cd34 mab  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34 mab
    Rat Anti Mouse Cd34 Mab, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 mab/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 mab - by Bioz Stars, 2024-04
    86/100 stars

    Images

    monoclonal rat anti mouse cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech monoclonal rat anti mouse cd34 antibody
    Monoclonal Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    86/100 stars

    Images

    cd34, mouse, mab mec14.7  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech cd34, mouse, mab mec14.7
    Cd34, Mouse, Mab Mec14.7, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34, mouse, mab mec14.7/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34, mouse, mab mec14.7 - by Bioz Stars, 2024-04
    93/100 stars

    Images

    rat anti mouse cd34 monoclonal antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34 monoclonal antibody
    Rat Anti Mouse Cd34 Monoclonal Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 monoclonal antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 monoclonal antibody - by Bioz Stars, 2024-04
    86/100 stars

    Images

    primary cd 34 rat monoclonal antimouse antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech primary cd 34 rat monoclonal antimouse antibody
    Primary Cd 34 Rat Monoclonal Antimouse Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary cd 34 rat monoclonal antimouse antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary cd 34 rat monoclonal antimouse antibody - by Bioz Stars, 2024-04
    86/100 stars

    Images

    rat anti cd34 monoclonal antibody mec 14 7  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti cd34 monoclonal antibody mec 14 7
    Rat Anti Cd34 Monoclonal Antibody Mec 14 7, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti cd34 monoclonal antibody mec 14 7/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti cd34 monoclonal antibody mec 14 7 - by Bioz Stars, 2024-04
    86/100 stars

    Images

    monoclonal rat anti mouse cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech monoclonal rat anti mouse cd34 antibody
    Monoclonal Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Hycult Biotech rat monoclonal anti cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars
      Buy from Supplier

    86
    Hycult Biotech rat anti mouse cd34 mab
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Anti Mouse Cd34 Mab, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 mab/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 mab - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    86
    Hycult Biotech monoclonal rat anti mouse cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Monoclonal Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    93
    Hycult Biotech cd34, mouse, mab mec14.7
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Cd34, Mouse, Mab Mec14.7, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34, mouse, mab mec14.7/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34, mouse, mab mec14.7 - by Bioz Stars, 2024-04
    93/100 stars
      Buy from Supplier

    86
    Hycult Biotech rat anti mouse cd34 monoclonal antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Anti Mouse Cd34 Monoclonal Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 monoclonal antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 monoclonal antibody - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    86
    Hycult Biotech primary cd 34 rat monoclonal antimouse antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Primary Cd 34 Rat Monoclonal Antimouse Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary cd 34 rat monoclonal antimouse antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary cd 34 rat monoclonal antimouse antibody - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    86
    Hycult Biotech rat anti cd34 monoclonal antibody mec 14 7
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Anti Cd34 Monoclonal Antibody Mec 14 7, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti cd34 monoclonal antibody mec 14 7/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti cd34 monoclonal antibody mec 14 7 - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    Image Search Results


    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Journal: bioRxiv

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    doi: 10.1101/2023.01.08.523169

    Figure Lengend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Article Snippet: Polyclonal rabbit anti-MCM6 (Proteintech, 13347-2-AP) and polyclonal rabbit anti-TIF1B/KAP1 (Merck Millipore, Sigma-Aldrich, ABE1859), mouse monoclonal anti-ICBP90/UHRF1 (Sigma-Aldrich, MABE308), rat monoclonal anti-HA-Peroxidase high affinity (Roche, Sigma-Aldrich, 12013819001), rabbit polyclonal anti-Actin (Sigma-Aldrich, A2103), mouse monoclonal anti-FLAG® M2-Peroxidase (Sigma-Aldrich, A8592), mouse monoclonal anti-Tropomyosin Ab (Sigma-Aldrich, T2780), goat polyclonal anti-rabbit IgG–Peroxidase antibody (Sigma-Aldrich, A6154), Alexa Fluor® 488 Goat Anti-Mouse IgG antibody (Molecular Probes, Invitrogen, A-11001, A11029), Alexa Fluor® 594 Goat Anti-Rabbit IgG antibody (Molecular Probes, Invitrogen, A-11012), Fluoroshield™ with DAPI (Sigma-Aldrich, F6057), Dynabeads™ CD25 (Invitrogen, Thermo Ficher Scientific, 11157D), rat monoclonal anti-CD34 antibody (HycultBiotech, HM1015), Polink-2 Plus HRP Rat-NM Bulk kit for DAB (GBI Labs, D46-110), rabbit monoclonal anti-Ki67 (Neomarkers; LabVision, Thermo Fisher Scientific, RM-9106), rabbit polyclonal cleaved Caspase-3 (Asp175) (Cell Signaling, 9661), anti-FLAG M2 affinity gel (Sigma-Aldrich, A 2220), FLAG® Peptide (Sigma-Aldrich, F3290), Protein A agarose (Pierce, Thermo Ficher Scientific, 20333).

    Techniques: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay